COSMOS Pharmaceutical Corporation (JP:3349)
:3349
Want to see JP:3349 full AI Analyst Report?
3349 Stock Chart & Stats
¥6699.00
¥109.00(1.60%)
At close: 4:00 PM EST
¥6699.00
¥109.00(1.60%)
Day’s Range― - ―
52-Week Range¥5,615.00 - ¥10,045.00
Previous CloseN/A
Volume659.40K
Average Volume (3M)399.89K
Market Cap
¥461.84B
Enterprise Value¥496.37B
Total Cash (Recent Filing)¥57.04B
Total Debt (Recent Filing)¥49.96B
Price to Earnings (P/E)14.7
Beta-0.22
Next Earnings
Jul 13, 2026EPS Estimate
117.37Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)390.85
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)2.72
Price to Sales (P/S)0.69
P/FCF Ratio-814.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)418.47
Revenue Forecast (FY)¥1.18T
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth indicates expanding market penetration of Cosmos' drugstore model and resilient consumer demand for pharmaceuticals and daily products. A multiyear revenue upswing supports scale benefits in procurement and merchandising, improving long-term cash generation potential and strategic reinvestment capacity.
Stable Margins And Operational EfficiencyConsistent gross and net margins alongside healthy EBIT/EBITDA margins reflect effective cost controls and merchandising mix management. This operational resilience supports profit sustainability through modest demand swings, enabling the company to maintain investments in stores and supply chain efficiency over multiple quarters.
Prudent Balance Sheet And Strong ROELow financial leverage and robust ROE demonstrate disciplined capital management and efficient use of equity. A strong equity ratio provides flexibility for store expansion, strategic investments or weathering economic stress, underpinning durable financial stability even as the company manages growth-related capital needs.
Bears Say
Negative Free Cash Flow TrendPersistent negative free cash flow, despite solid operating cash inflows and earnings, signals that capital expenditures or working capital demands are outpacing cash generation. Over months this reduces liquidity optionality for dividends, deleveraging or opportunistic investments and raises funding risk if not reversed.
Increase In Total DebtRising absolute debt levels, even from a low base, can erode financial flexibility if sustained—especially alongside negative FCF. Continued debt accumulation may increase interest burden and limit capacity for strategic spending, making capital structure management a material medium-term risk to credit strength.
Pressure On Operating MarginA recent dip in EBIT margin points to emerging cost pressures (labor, rent, procurement or promotional activity). If such trends persist, the company may face margin compression in a low-price, competitive retail environment, requiring efficiency gains or price adjustments to preserve long-term profitability.
COSMOS Pharmaceutical Corporation News
3349 FAQ
What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?
COSMOS Pharmaceutical Corporation lowest stock price was ¥5615.00 and its highest was ¥10045.00 in the past 12 months.
What is COSMOS Pharmaceutical Corporation’s market cap?
COSMOS Pharmaceutical Corporation’s market cap is ¥461.84B.
When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?
COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Jul 13, 2026 which is in 35 days.
How were COSMOS Pharmaceutical Corporation’s earnings last quarter?
COSMOS Pharmaceutical Corporation released its earnings results on Apr 13, 2026. The company reported ¥102.19 earnings per share for the quarter, beating the consensus estimate of ¥100.689 by ¥1.501.
Is COSMOS Pharmaceutical Corporation overvalued?
According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Overvalued.
Does COSMOS Pharmaceutical Corporation pay dividends?
COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here
What is COSMOS Pharmaceutical Corporation’s EPS estimate?
COSMOS Pharmaceutical Corporation’s EPS estimate is 117.37.
How many shares outstanding does COSMOS Pharmaceutical Corporation have?
COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.
What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?
COSMOS Pharmaceutical Corporation reported an EPS of ¥102.19 in its last earnings report, beating expectations of ¥100.689. Following the earnings report the stock price went down -1.122%.
Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?
Currently, no hedge funds are holding shares in JP:3349
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
Create SD Holdings Co., Ltd.
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Options Prices
Currently, No data available
---